UNSPSC 51112525: Trofosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C9H18Cl3N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H64JRU6GJ0, chemically known as 3-(2-chloroethyl)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin 2-oxide but more generally known as trofosfamide, which bears US NIH Compound Identifier 65702. European Medicines Agency schedules Trofosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11331MIG.

UNSPSC 51112525 Trofosfamide, a Commodity code, covers the procurement of trofosfamide, a nitrogen mustard-based alkylating chemotherapy agent used in cancer treatment protocols. State and local governments—primarily health departments, state Medicaid programs, public hospital systems, and county health authorities—purchase trofosfamide to support oncology services and inpatient chemotherapy programs. The drug is typically procured through pharmaceutical supply contracts, GPOs (group purchasing organizations), or direct state health-agency purchasing to stock hospital pharmacies and outpatient infusion centers.

The source provides no recent state and local contract opportunities under this code. Activity visibility is limited; trofosfamide procurement at the state and local level occurs primarily through standing pharmaceutical supply agreements and statewide Medicaid drug formulary channels rather than through discrete solicitations. Procurement professionals should monitor state health department RFPs for oncology pharmaceutical supply, state Medicaid agency drug-formulary updates, and hospital system GPO contracts as indirect signals of trofosfamide demand.